Developed by two American tech companies, the revolutionary counter-drone technology has shown potential to take down threats in combat.

First breakthrough in treating asthma attacks in 50 years hailed as a ‘game-changer’ - Benralizumab is a monoclonal antibody that targets specific white blood cells

Benralizumab is what’s known as a monoclonal antibody, which replicates properties of a normal antibody produced by the immune system. The antibody targets a specific group of white blood cells (called eosinophils) to reduce lung inflammation.

Benralizumab is a monoclonal antibody that targets specific white blood cells, called eosinophils, to reduce lung inflammation.

King’s College, London researchers say they have found the first new treatment for asthma attacks in 50 years. Benralizumab injection dampens part of the immune system that can go into overdrive in flare-ups of both asthma and chronic obstructive pulmonary disease and can be used routinely.